SOFTOX SOLUTIONS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.218 NOK | +2.83% |
|
-0.91% | -93.27% |
| 18/04 | Transcript : SoftOx Solutions AS - Special Call | |
| 20/03 | SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 7.9M 717K 59.76M | Sales 2022 | 7.11M 645K 53.8M | Capitalization | 241M 21.86M 1.82B |
|---|---|---|---|---|---|
| Net income 2021 | -65M -5.9M -492M | Net income 2022 | -71M -6.44M -537M | EV / Sales 2021 | 64.3 x |
| Net cash position 2021 | 56.98M 5.17M 431M | Net cash position 2022 | 6.91M 626K 52.23M | EV / Sales 2022 | 32.9 x |
| P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-3.39
x | Employees | 25 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on SoftOx Solutions
More press releases
| 1 day | +2.83% | ||
| 1 week | -0.91% | ||
| Current month | -51.56% | ||
| 1 month | -73.54% | ||
| 3 months | -88.59% | ||
| 6 months | -95.40% | ||
| Current year | -93.27% |
1 week
0.20
0.25
1 month
0.200.70
Current year
0.203.99
1 year
0.209.80
3 years
0.2079.70
5 years
0.20116.00
10 years
0.20116.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Geir Almås
FOU | Founder | - | 21/12/21 |
Harald Sætvedt
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Olav Jarlsby
BRD | Director/Board Member | - | 17/15/17 |
Geir Almås
FOU | Founder | - | 21/12/21 |
Adrian Bignami
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.218 | +2.83% | 349,504 |
| 25/24/25 | 0.212 | +4.95% | 1,749,468 |
| 24/24/24 | 0.202 | -1.46% | 269,373 |
| 23/24/23 | 0.205 | -1.44% | 1,309,280 |
| 22/24/22 | 0.208 | -5.45% | 38,257 |
Real-time Oslo Bors, April 26, 2024 at 08:15 pm IST
More quotes
SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.
Calendar
04/09/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -93.27% | 9.94M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SOFTX Stock
